Hypoxia Inducible Factor-1alpha and Vascular Endothelial Growth Factor in Biopsies of Small Cell Lung Carcinoma
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Neoangiogenesis has been documented in small cell lung carcinoma (SCLC). In addition, antiangiogenic therapies are being tested in clinical trials that involve SCLC. However, study of the underlying mechanisms has been performed almost exclusively in cell lines. In the current study, we immunostained 30 biopsy samples of SCLC with antibodies to hypoxia inducible factor-1 alpha (HIF-1 alpha), vascular endothelial growth factor (VEGF), vascular endothelial growth factor-receptor 1 (VEGF-R1/flt-1) and vascular endothelial growth factor-receptor 2 (VEGF-R1/flk-1). The immunoreactivity was analyzed using a bivariate Spearman correlation test and linear regression analysis. We found significant correlation between HIF-1 alpha nuclear staining and VEGF staining. Moreover HIF-1 alpha+/VEGF+ cases were associated with poor survival. We also found a positive correlation between VEGF and VEGF-R2 expression. We suggest that a HIF-1 alpha/VEGF angiogenic pathway may exist in vivo in SCLC, similar to that in non-SCLC. Our data also suggest a potential VEGF/VEGFR-2 autocrine pathway in SCLC. The inclusion of novel inhibitors to HIF-1 alpha and other factors may optimize antiangiogenic interventions in SCLC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIF-1 is overexpressed in 30 to 62% of NSCLC and 43 to 46% of SCLC cases, and its overexpression has been associated with poorer overall survival.10 –15”
From Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice (2010) · cites this paper as [14]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“In human tumors, HIF-1a also can be over-expressed in nonhypoxic conditions, such as the activation of protein kinase B (AKT) in prostate cancer cells [38], the loss of von-Hippel‐Lindau protein in renal cancer cells [ 39 ], and the increased activity of reactive oxygen species in gastric cancer cells [40].”
BackgroundActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981 · cited 1×
“However, it is generally known that the hypoxia inducible factor-1a (HIF-1a) is involved in the transcriptional regulation of VEGF [6, 7].”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“After heterodimerization with the protein HIF-1b, a nuclear translocator that is expressed constitutively and remains unaffected by hypoxia, HIF-1 binds to DNA at the hypoxia response elements (HREs) and it activates the VEGF gene, one of the key angiogenic stimulators [8].”
BackgroundSoker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463 · cited 1×
“VEGF binds with high affinity to its cognate receptors, flt-1/VEGFR-1, flk1/KDR/VEGFR-2, and neuropilin-1 [11–13].”
Background(1999) · PubMed · Cited by 2,204
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., & Heldin, C. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47116-5 · Cited by 1,656 · cited 1×
“VEGFR-2 is responsible for mitogenic signalling, whereas while VEGFR-1 participates in cell migration [14–17].”
BackgroundHIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579 · cited 2×
“However, it is generally known that the hypoxia inducible factor-1a (HIF-1a) is involved in the transcriptional regulation of VEGF [6, 7].”
BackgroundIdentification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519 · cited 1×
“VEGF binds with high affinity to its cognate receptors, flt-1/VEGFR-1, flk1/KDR/VEGFR-2, and neuropilin-1 [11–13].”
Background(2000) · PubMed · Cited by 1,445
Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marme, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,356 · cited 2×
“Previous studies also have demonstrated VEGFR1 and VEGFR2 expression in tumor cells [15–18].”
BackgroundResultTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312 · cited 1×
“growth factor-2, and inducible nitric oxide synthetase [7, 9, 10].”
BackgroundRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,241
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities
Clauss, M., Weich, H., Breier, G., Knies, U., Röckl, W., Waltenberger, J., & Risau, W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17629 · Cited by 836
Wang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
(2000) · PubMed · Cited by 614
(2001) · PubMed · Cited by 605
Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
Mukhopadhyay, D., Tsiokas, L., Zhou, X.-M., Foster, D., Brugge, J. S., & Sukhatme, V. P. (1995) · Nature · doi:10.1038/375577a0 · Cited by 595 · cited 1×
“In vitro studies have demonstrated that the addition of VEGF-A increases the growth of cells withVEGFR2 [19, 20], which suggests both an autocrine and a paracrine regulation of tumor growth [21–23].”
BackgroundGiatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2018 · Cited by 478
Enholm, B., Paavonen, K., Ristimäki, A., Kumar, V., Gunji, Y., Klefstrom, J., Kivinen, L., Laiho, M., Olofsson, B., Joukov, V., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201090 · Cited by 457 · cited 1×
“Previous studies also have demonstrated VEGFR1 and VEGFR2 expression in tumor cells [15–18].”
ResultMasood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., & Gill, P. S. (2001) · Blood · doi:10.1182/blood.v98.6.1904 · Cited by 343 · cited 1×
“VEGFR-2 expression in the tumor cells may thus predict for better response to VEGF ablation [ 45 ].”
BackgroundTHEODOROPOULOS, V (2004) · European Urology · doi:10.1016/j.eururo.2004.04.008 · Cited by 223
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
Ohta, Y., Endo, Y., Tanaka, M., Shimizu, J., Oda, M., Hayashi, Y., Watanabe, Y., & Sasaki, T. (1996) · PubMed · Cited by 183
The role of hypoxia-inducible factors in cancer
Maynard, M. A., & Ohh, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7082-2 · Cited by 154 · cited 1×
“It has been noted that an indirect ‘‘assaying’’ of a given HIF-1a-mediated response can be accomplished by showing overexpression of selected, ‘‘downstream’’ target genes [41].”
BackgroundSmall cell lung carcinoma (SCLC): the angiogenic phenomenon
Lucchi, M., Mussi, A., Fontanini, G., Faviana, P., Ribechini, A., & Angeletti, C. A. (2002) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(02)00112-4 · Cited by 152 · cited 3×
“Both an increased MVD and a parallel VEGF overexpression have been associated with poor prognosis in patients with SCLC, thus inviting applications of traditional antiangiogenic medications [2, 4 ]. There is, however, more data and perhaps more interest beyond such a traditional antiangiogenic approach in SCLC.”
BackgroundResultInfluentialHypoxia-inducible factor (HIF) in human tumorigenesis.
Mabjeesh, N. J., & Amir, S. (2007) · PubMed · doi:10.14670/hh-22.559 · Cited by 141 · cited 1×
“This method has been used extensively in many tumor types [33, 34].”
MethodELIAS, A. D. (1997) · CHEST Journal · doi:10.1378/chest.112.4_supplement.251s · Cited by 135
Transcriptional regulation of vascular endothelial growth factor in cancer
LOUREIRO, R., & D'Amore, P. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.005 · Cited by 133 · cited 1×
“Notably, VEGF expression can be upregulated by other factors, including cytokines, such as interleukin (IL)-1, activation of certain oncogenes (Ras, Raf, Src), and loss-of-function mutations of p53 and the von Hippel–Lindau genes [42].”
BackgroundPark, J.-H., Kim, T. Y., Jong, H.-S., Kim, T. Y., Chun, Y., Park, J., Lee, C., Jung, H. C., Kim, N. K., & Bang, Y. (2003) · PubMed · Cited by 125
Triantafyllou, A., Liakos, P., Tsakalof, A., Georgatsou, E., Simos, G., & Bonanou, S. (2006) · Free Radical Research · doi:10.1080/10715760600730810 · Cited by 120
Self-citationLitz, J., & Krystal, G. W. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0503 · Cited by 93 · cited 3×
“This approach is currently being tested in clinical trials [2, 3].”
BackgroundMethodPedersen, M. W. B., Holm, S., Lund, E. L., Hojgaard, L., & Kristjansen, P. E. G. (2001) · Neoplasia · doi:10.1038/sj.neo.7900133 · Cited by 86 · cited 1×
“Similar data on SCLC are limited, especially in clinical samples [ 26 , 27].”
ResultWang, D., Donner, D. B., & Warren, R. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001847200 · Cited by 77 · cited 2×
“Previous studies also have demonstrated VEGFR1 and VEGFR2 expression in tumor cells [15–18].”
BackgroundResultA Diagnostic Clue and Potential Pitfall
Gaudin, P. B., & Rosaí, J. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199506000-00004 · Cited by 73 · cited 1×
“including SCLC [43].”
Enatsu, S., Iwasaki, A., Shirakusa, T., Hamasaki, M., Nabeshima, K., Iwasaki, H., Kuroki, M., & Kuroki, M. (2006) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2006.03.027 · Cited by 42 · cited 1×
“It is reported as a common event associated with poor prognosis [24, 25 ].”
BackgroundÜstüner, Z., Saip, P. M., Yasasever, V., Vural, B., Yazar, A., Bal, C., Öztürk, B. Ö., Özbek, U., & Topuz, E. (2008) · Medical Oncology · doi:10.1007/s12032-008-9052-4 · Cited by 39 · cited 1×
“A similar interrelation has been reported previously in serum measurements of SCLC patients [44].”
BackgroundOkajima, E., & Thorgeirsson, U. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2386 · Cited by 37 · cited 1×
“In vitro studies have demonstrated that the addition of VEGF-A increases the growth of cells withVEGFR2 [ 19 , 20], which suggests both an autocrine and a paracrine regulation of tumor growth [21‐23].”
BackgroundMgcRacGAP Interacts with HIF-1α and Regulates its Transcriptional Activity
Lyberopoulou, A., Venieris, E., Mylonis, I., Chachami, G., Pappas, I., Simos, G., Bonanou, S., & Georgatsou, E. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110460 · Cited by 36 · cited 1×
“Sections from pelleted HeLa cells lines cultured under hypoxic conditions (the iron-chelator desferrioxamine-DFO was added) were considered as positive controls [28–30].”
MethodSelf-citationThe role of new targeted therapies in small-cell lung cancer
Rossi, A., Maione, P., Colantuoni, G., Guerriero, C., & Gridelli, C. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.003 · Cited by 21 · cited 3×
“This approach is currently being tested in clinical trials [2, 3].”
BackgroundMethod[Expression of HIF-1 alpha and its relationship to apoptosis and proliferation in lung cancer].
Fan, L., Diao, L., Chen, D.-J., Liu, M., Zhu, L., Li, H., Tang, Z., Xia, D., Liu, X., & Chen, H. (2002) · PubMed · Cited by 20
(1995) · PubMed
(1996) · PubMed
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 436
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
HIF and the Lung: Role of Hypoxia-inducible Factors in Pulmonary Development and Disease
Shimoda, L. A., & Semenza, G. L. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1393pp · Cited by 277
Cheng, Y., Wang, Q., Li, K., Shi, J., Liu, Y., Wu, L., Han, B., Chen, G., He, J., Wang, J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01356-3 · Cited by 166
Metadata
- Authors
- Ioannou, M., Papamichali, R., Kouvaras, E., Mylonis, I., Vageli, D., Kerenidou, T., Barbanis, S., Daponte, A., Simos, G., Gourgoulianis, K., & Koukoulis, G. K.
- Affiliations
- University of Thessaly (GR)
- Venue
- Lung
- Published
- 2009-08-26
- Volume
- 187
- Issue
- 5
- Pages
- 321-329
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W2002503852
- Cited by
- 57
- References
- 46
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- small cell lung cancer, hypoxia-inducible factor-1α, vascular endothelial growth factor, VEGF receptor 2, VEGF receptor 1, tumor angiogenesis, autocrine signaling, anti-angiogenic therapy, prognosis, tumor hypoxia
- MeSH terms
- Aged, Aged, 80 and over, Biopsy, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Time Factors, Linear Models, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Hypoxia-Inducible Factor 1, alpha Subunit, Kaplan-Meier Estimate, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.